-
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
•
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed in a London Stock Exchange filing its intention to pursue legal action against China’s genomics powerhouse BGI and its affiliates. The company alleges that BGI’s newly launched nanopore-based sequencing platform infringes upon or misappropriates Oxford…
-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced an unsuccessful market filing for its BRCA1/2 gene mutation detection kit, which utilizes the combined probe anchored polymerization sequencing method. The company cited the failure to complete the required complement and correction of information as…
-
BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms
•
US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would restrict interactions between US companies and several Chinese life sciences firms. According to details obtained by FiercePharma.com from recent amendments to the draft law, existing contracts between US firms and the listed Chinese entities will…
-
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
•
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity” bill proposal that could have significant implications for the biotechnology industry. The bipartisan-supported bill aims to prohibit companies receiving US government funding from engaging in commercial dealings with certain biotech companies identified as national security…
-
Bristol-Myers Squibb Prepares Contingency Plans in Response to the Biosecure Act
•
Bristol-Myers Squibb (BMS; NYSE: BMY), a leading U.S. pharmaceutical company, is reportedly drafting ‘contingency plans’ to address the potential implications of the Biosecure Act, which is currently under legislative review in the United States. As detailed by the Financial Times, BMS’s CFO, David Elkins, disclosed on a media call that…
-
BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit
•
BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced the approval of its medical device license from the National Medical Products Administration (NMPA) for a novel gene methylation detection kit. The kit employs fluorescence PCR technology to assess the combined methylation status of the…
